---
id: FC-133
type: Flashcard
created: 2025-08-08 09:59:51.738864
tags:
- Flashcard
- question
- endocrine
topic: endocrine
answer: A
related_articles:
- title: 'Chronic Kidney Disease: Prevention, Diagnosis, and Treatment.'
  path: 2023/2023-12-chronic-kidney-disease-prevention-diagnosis-and-treatment.md
  similarity: 0.643
  link: '[[2023/2023-12-chronic-kidney-disease-prevention-diagnosis-and-treatment|Chronic
    Kidney Disease: Prevention, Diagnosis, and Treatment.]]'
- title: In Older Adults With Type 2 Diabetes, GLP-1 Receptor Agonists Decrease Major
    Adverse Cardiovascular Events; SGLT-2 Inhibitors Prevent Heart Failure Hospitalizations.
  path: 2025/2025-03-in-older-adults-with-type-2-diabetes-glp-1-receptor-agonists.md
  similarity: 0.636
  link: '[[2025/2025-03-in-older-adults-with-type-2-diabetes-glp-1-receptor-agonists|In
    Older Adults With Type 2 Diabetes, GLP-1 Receptor Agonists Decrease Major Adverse
    Cardiovascular Events; SGLT-2 Inhibitors Prevent Heart Failure Hospitalizations.]]'
- title: Liraglutide Is Probably the Best Second Drug to Prevent Cardiovascular Events
    in Patients With Type 2 Diabetes Mellitus Who Take Metformin.
  path: 2023/2023-04-liraglutide-is-probably-the-best-second-drug-to-prevent-card.md
  similarity: 0.636
  link: '[[2023/2023-04-liraglutide-is-probably-the-best-second-drug-to-prevent-card|Liraglutide
    Is Probably the Best Second Drug to Prevent Cardiovascular Events in Patients
    With Type 2 Diabetes Mellitus Who Take Metformin.]]'
- title: Finerenone (Kerendia) for the Treatment of Chronic Kidney Disease in Patients
    With Type 2 Diabetes Mellitus.
  path: 2023/2023-09-finerenone-kerendia-for-the-treatment-of-chronic-kidney-dise.md
  similarity: 0.6
  link: '[[2023/2023-09-finerenone-kerendia-for-the-treatment-of-chronic-kidney-dise|Finerenone
    (Kerendia) for the Treatment of Chronic Kidney Disease in Patients With Type 2
    Diabetes Mellitus.]]'
- title: DPP-4 Inhibitors, GLP-1 Receptor Agonists, and SGLT-2 Inhibitors for People
    With Cardiovascular Disease.
  path: 2022/2022-07-dpp-4-inhibitors-glp-1-receptor-agonists-and-sglt-2-inhibito.md
  similarity: 0.6
  link: '[[2022/2022-07-dpp-4-inhibitors-glp-1-receptor-agonists-and-sglt-2-inhibito|DPP-4
    Inhibitors, GLP-1 Receptor Agonists, and SGLT-2 Inhibitors for People With Cardiovascular
    Disease.]]'
topics:
- Cardiology
- Emergency Medicine
- Endocrinology
- Nephrology
- Psychiatry
---

# Flashcard FC-133

## Question

Yourpatientwithtype2 diabeteshashadmicroalbuminuria(albuminlevel30-300 mgper day)ontwo separateoccasionsatleast3 monthsapart. which one of the followingstatementsregardingtheuseof angiotensin-convertingenzyme(ACE)inhibitorsorangiotensinreceptorblockers(ARBs)inpatientswith diabeticnephropathyis correct? Theyreduceprogressiontoend-stagekidneydisease. Theyreduceall-causemortality. Theyreducecardiovascularmortality. Alloftheabove. @ Back

## Answer

**A**

## Explanation

Ina Cochranereviewof109 studieswith28,341 patients,ARBtherapypreventeddoublingofserum creatinineoverthecourseof3 yearsandprogressionfrommicroalbuminuriatomacroalbuminuriaover thecourseof2 years,whereas ACEinhibitortherapypreventedprogressionfrommicroalbuminuriato macroalbuminuria. Resultssuggestthattheymaycontributetoregressionofmicroalbuminuria. Therewasinsufficientevidencetodeterminethecomparativesuperiorityof ACEinhibitoror ARBtherapy onkidneyoutcomes,anditisunclearwhetherdualtherapy(ie,simultaneoususeof ACEinhibitorand ARB)offersanybenefitovermonotherapy. ACEinhibitorsand ARBsdidnotreduceall-causeor cardiovascularmortality. e

## References

- AAFPQuestion Bank-Pythonsimplecapture.

